Clinical Trials
4 trialsNCT04760288 2024-01-05
AcceleRET-MTC
Hoffmann-La Roche
Phase 3 Withdrawn
NCT04151563 2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2 Withdrawn
NCT05039736 2023-05-12
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05327738 2022-12-14
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn